Zynerba reports additional data for epilepsy candidate ZYN002

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) reported data from 171 patients with confirmed refractory epilepsy with focal seizures with or without secondary generalization who completed the Phase II STAR 1 trial and were enrolled in the STAR 2 open-label extension of ZYN002. The company reported a median seizure reduction of 65% from baseline in patients who received 195 mg ZYN002 for three months in STAR 1 followed by 390 mg ZYN002 for six months in STAR 2, and a median seizure reduction of 48% in patients receiving 390 mg ZYN002 for three months in STAR 1 followed by 390 mg ZYN002 for six months in STAR 2. In patients receiving placebo for three months in STAR 1 followed by 390 mg ZYN002 for six months in STAR 2, the median seizure reduction was 27%. Data were presented at the American Epilepsy Society meeting in Washington D.C.

The company previously reported that both doses of ZYN002 missed the STAR 1 primary endpoint of improving the median percent reduction in focal seizure frequency from baseline to week 12 vs. placebo (see BioCentury, Aug. 11)...